Instead of IPO, Aptalis takes $2.9bn acquisition offer from Forest Laboratories
Less than two weeks after filing an S-1 to go public, private spec pharma Aptalis Holdings Inc. scrapped those plans and instead agreed to be acquired by Forest Laboratories Inc. for $2.9bn in cash.
- Drug Delivery
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com